Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis. - Wikidata - awgldk - TriplyDB

Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis.

Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis.

http://www.wikidata.org/entity/Q37143744

about

The adjuvant use of calcium fructoborate and borax with etanercept in patients with rheumatoid arthritis: Pilot study.

P2860

Q37621159-1FEC705E-AAB4-4612-8E21-B5FAA01B9506

P2860

Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis.

http://www.wikidata.org/entity/Q37143744

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 June 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Clinical Outcomes and Biologic ...... ans with Rheumatoid Arthritis.

@en

Clinical Outcomes and Biologic ...... ans with Rheumatoid Arthritis.

@nl

type

label

Clinical Outcomes and Biologic ...... ans with Rheumatoid Arthritis.

@en

Clinical Outcomes and Biologic ...... ans with Rheumatoid Arthritis.

@nl

prefLabel

Clinical Outcomes and Biologic ...... ans with Rheumatoid Arthritis.

@en

Clinical Outcomes and Biologic ...... ans with Rheumatoid Arthritis.

@nl

P1433

Q37143744-F261C87A-5885-4518-9240-199BC24D36A5

P1476

Q37143744-5266CF06-7AAB-417E-A8DB-B3AC385652F0

P2093

Q37143744-0918C148-7D04-4902-8C9C-D17E1238C14D

Q37143744-2A877CA3-580B-4026-9778-9EA9757BF5B1

Q37143744-31009F88-A80F-4814-962F-8BF47C143B7D

Q37143744-3E7510E5-C96F-4677-AE1A-0C4A3A128F3E

Q37143744-804529CF-49B0-47AB-922D-0D6365948F1B

Q37143744-8ABC31E9-AD44-4FF3-BFEA-3AD48408C6B2

Q37143744-A765A8C9-FA1C-499A-81DF-CF94C55B43A1

Q37143744-AB57EBC1-7916-4FE8-BB14-D337EC52ABA9

Q37143744-BF6FD947-26F9-4BA0-A803-4CD2EDCAA4C9

Q37143744-D2910F57-839F-4A36-924D-39510F556BAE

P2860

Q37143744-08496A9F-FCA7-42AC-9795-CCADA495A54F

Q37143744-0CFFA086-8EA6-44E6-826E-47F52D3180EB

Q37143744-0EE9E09C-43EE-4EA9-9559-C1E9A99108F2

Q37143744-20D999EF-D2AF-4753-992A-99B7DBBD0D95

Q37143744-3AD63A2E-FD09-480B-A5A7-27FFA87A686A

Q37143744-4BA02CCB-FD36-4EB2-A166-724D93C3D5BF

Q37143744-51E10ED7-4270-4991-A8D1-21E690D4E992

Q37143744-5ADB00B9-2F5E-4EAA-92FD-11BADD362B5C

Q37143744-5FDEE431-D808-4015-8C0B-F40653EF9358

Q37143744-6473F73F-A0F8-4448-BD9E-7A34656B2518

P2888

Q37143744-8F2B24C4-D14A-4738-A845-1DC43AC311E2

P304

Q37143744-F10A01DF-1C59-44C3-9A23-949B0692AE05

P31

Q37143744-69012AE8-3118-4626-B6DC-AC108D8DF899

P356

Q37143744-6317B2BE-149B-4843-9CF7-380D37477558

P407

Q37143744-C1E30D4C-445C-40C1-88D3-810A7345855E

P433

Q37143744-0A836D85-73A9-493C-88EF-5BB4D4ED91DE

P478

Q37143744-906C125A-49CD-4AFF-BD1D-CA36E7B7EE24

P50

Q37143744-B010F800-344E-4422-8BDA-C8C8C1C62277

P577

Q37143744-DBE6DB5C-AB58-4462-8B1D-385E178B0A93

P698

Q37143744-41CD50DB-95A6-44FB-ACB3-BBEF30053454

P932

Q37143744-C1C64F2D-9B29-48E6-9EB1-9316AA2D3DE8

P356

S12325-016-0371-0

P1433

Advances in Therapy

P1476

Clinical Outcomes and Biologic ...... rans with Rheumatoid Arthritis

@en

P2093

Andreas Reimold

http://www.w3.org/2001/XMLSchema#string

Candace L Haroldsen

http://www.w3.org/2001/XMLSchema#string

David H Collier

http://www.w3.org/2001/XMLSchema#string

David J Harrison

http://www.w3.org/2001/XMLSchema#string

George J Joseph

http://www.w3.org/2001/XMLSchema#string

Grant W Cannon

http://www.w3.org/2001/XMLSchema#string

Jeffrey R Curtis

http://www.w3.org/2001/XMLSchema#string

Kaleb Michaud

http://www.w3.org/2001/XMLSchema#string

Liron Caplan

http://www.w3.org/2001/XMLSchema#string

Scott L DuVall

http://www.w3.org/2001/XMLSchema#string

P2860

Biologic agents in rheumatoid arthritis: an update for managed care professionals

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.

Pharmacy data in the VA health care system.

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.

Outcomes of switching anti-TNF drugs in rheumatoid arthritis--a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN).

Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States.

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

P2888

s12325-016-0371-0

P304

1347-1359

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12325-016-0371-0

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-06-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27352377

http://www.w3.org/2001/XMLSchema#string

P932

4969320

http://www.w3.org/2001/XMLSchema#string